GFP
ALXN

Gryphon Financial Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Gryphon Financial Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-114
Closed -$14K – 903
2018
Q2 		$14K Sell
114
-8
-7% -$935 0.01% 449
2018
Q1 		$14K Sell
122
-32
-21% -$3.83K 0.01% 453
2017
Q4 		$18K Buy
+154
New +$18.8K 0.01% 427

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Gryphon Financial Partners's ALXN Position: Q3 2018 in Review

Gryphon Financial Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 114 shares — an estimated $14K sold.

Gryphon Financial Partners first reported a position in ALXN in Q4 2017 and held it in 3 quarters. The position peaked at $18K in Q4 2017. 584 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Gryphon Financial Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 114 Alexion Pharmaceuticals shares in Q3 2018, an estimated $14K.
  • Gryphon Financial Partners first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Gryphon Financial Partners's Alexion Pharmaceuticals position peaked at $18K in Q4 2017.
  • 584 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Gryphon Financial Partners's 13F filing for Q3 2018, filed 6 Nov 2018.